Table 3B: Overall
survival in relation to OC use, stratified by age at diagnosis.
|
n |
HR crude (95%
CI) |
d/m |
HR adjustedc (95%
CI) |
d/m |
HR adjustedd (95% CI) |
d/m |
41-55 |
116 |
|
24/0 |
|
23/1 |
|
19/48 |
OC never |
30 |
1.00 |
8/0 |
1.00 |
8/0 |
1.00 |
7/15 |
OC ever |
86 |
0.68 (0.29-1.59) |
16/0 |
0.72 (0.30-1.74) |
15/1 |
0.72 (0.22-2.30) |
12/33 |
56-70 |
471 |
|
101/0 |
|
98/5 |
|
55/ 223 |
OC never |
204 |
1.00 |
49/0 |
1.00 |
49/1 |
1.00 |
32/96 |
OC ever |
267 |
0.96 (0.65-1.42) |
52/0 |
0.90 (0.60-1.34) |
49/4 |
0.72 (0.41-1.25) |
23/127 |
71- |
177 |
|
65/0 |
|
64/3 |
|
33/80 |
OC never |
130 |
1.00 |
58/0 |
1.00 |
57/3 |
1.00 |
30/59 |
OC ever |
47 |
0.33 (0.15-0.72)* |
7/0 |
0.34 (0.16-0.76)* |
7/0 |
0.38 (0.11-1.30) |
3/21 |
N(number) stands for total
cases included in the analysis, d for total deaths in analyses and m for
missing data.
cAdjusted
for BMI, and socioeconomic status
dAdjusted for BMI, socioeconomic status,
size of tumor, lymphnod einvolvement, grade of tumor (according to Nottingham),
PgR, ER, HER2, P27, Ki67.
*Significance.
Confidence interval separate from 1.00